Oncology Institute (TOI) new name to me spiked earlier with unusual 7000 November $4 calls bought $0.25 to $0.30, IV30 up 30% here. Shares are up 1100% YTD with just 5.5% of the float short and a market cap of $350M. The Oncology Institute (TOI) is a leading, value-based oncology company in the United States operating a large network of community-based oncology practices. TOI focuses on delivering comprehensive cancer care, integrating advanced medical treatments with accessible, patient-centered services and leveraging value-based care models to improve outcomes while managing costs. TOI provides a wide range of services including medical oncology, radiation oncology, hematology, surgical oncology, supportive care, and access to clinical trials. Their approach includes personalized treatment plans, multidisciplinary care teams, and supportive services (like palliative care and counseling) to address both medical and quality-of-life needs for patients. TOI is differentiated by its integrated care model, designed for community settings rather than academic hospitals, which increases accessibility for local patients. The company prioritizes value-based care, aiming to optimize health outcomes while controlling costs, and manages around 1.8 million patients under such agreements. TOI is forecasting $460M-$480M in revenues for FY25, so its market cap is less than revenues with it operating at a loss. TOI could be a beneficiary of the cost containment trend.